$LNAI News

Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister

Lunai Bioworks Requests Immediate Nasdaq Trading Suspension Amid Allegations Of Short Selling And Failures To Deliver

Lunai Bioworks Files For Non Timely 10-K With U.S. SEC; Anticipates Reporting A Net Loss For The Fiscal Year Ended June 30, 2026 Of ~$3.2M

Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement

Lunai Bioworks Enters Exclusive Worldwide License And Collaboration Agreement With Tanaist To Add Human Cellular Phenotyping To Its Parkinson's Disease Discovery And Validation Platform

Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Lunai Bioworks Files Second Amended Complaint Against Six Registered Broker-Dealers And Two Broker-Dealer Principals As Defendants In U.S. District Court, Delaware

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

Lunai Bioworks Files Amended RICO Complaint Expanding Naked Short-Selling Lawsuit; Names 10 Defendants, Including 3 FINRA Registered Broker Dealers, In Connection With An Alleged Coordinated Naked Short Selling Scheme That The Company Says Generated Failures To Deliver On More Than 81% Of Its Outstanding Shares

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Why Did LNAI Stock Soar Over 100% In Pre-Market Trading Today?

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

Lunai Bioworks Regains Nasdaq Compliance

Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration

Lunai Bioworks' BioSymetrics And BrainStorm Therapeutics Announce Strategic Collaboration And LOI Integrating AI Discovery, Human Brain Organoid Modeling, And In Vivo Validation To Generate Differentiated Neurology Assets For Pharmaceutical Partnering And Development

LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT

Lunai Bioworks Inc. - Common Stock Q3 EPS $(0.10), Sales $20.942K

Lunai Bioworks Approves Reverse Stock Split At Ratio Of 1-For-3 To 1-For-30